- $1.06bn
- $1.26bn
- $272.30m
Harrow Health swings to profit in Q2
Brief: Harrow Enters Into Commercialization Agreement With Samsung Bioepis For Ophthalmology Biosimilars Portfolio In The United States
Brief: Samsung Bioepis Enters Into A Partnership With Harrow For Commercialization Of Ophthalmology Biosimilars Portfolio In United States
Brief: Harrow Acquires U.S. Commercial Rights To Byqlovi™ From Formosa Pharmaceuticals
Harrow Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Harrow - Klarity-C Patients To Access Vevye For $59 Per Bottle
Harrow Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Harrow Inc Reports Fourth-Quarter & Year-End 2024 Audited Financial Results
U.S. STOCKS ON THE MOVE-Aditxt, Natgas companies, DocuSign
U.S. STOCKS ON THE MOVE-Ralph Lauren, Gold miners, Aditxt
U.S. STOCKS ON THE MOVE- Block, KBR, Sarepta Therapeutics
U.S. STOCKS ON THE MOVE- Tesla, Block, Alibaba Group
Harrow jumps on predicting Q4 sales above estimate
Brief: Harrow Executes Five-Year Strategic Supply And Development Agreement For TRIESENCE
U.S. STOCKS ON THE MOVE-Super Micro Computer, WEX, MarketAxess
U.S. STOCKS ON THE MOVE-Peloton, InterDigital, Pagaya
Harrow rises after H.C. Wainwright starts coverage with 'buy' rating
Advisory: Alerts on Melt Pharmaceuticals wrongly tagged to Harrow Inc withdrawn
U.S. STOCKS ON THE MOVE-Talen Energy, Biogen, Ovintiv